clinical trials

WHAT WE DO Overview Drug Discovery Bacterial Repository Clinical Scientific Expertise Specialized Microbiology Laboratory Services Clinical Development Central Laboratory Microbiology Services Clinical Scientific Expertise Specialized Microbiology Laboratory Services Regulatory Submissions Antimicrobial Resistance Surveillance Central Laboratory Microbiology Services Clinical Scientific Expertise Specialized Microbiology Laboratory Services Commercialization Antimicrobial Resistance Surveillance Antimicrobial Voluntary Evaluation Program (AVEP) Clinical Scientific Expertise Manufacturers Interface and Performance Program (MIPP) Specialized Microbiology Laboratory Services Your Global Antimicrobial Partner IHMA supports all phases of anti-infective therapy development, from discovery through commercialization. We are your essential resource for central, reference, and clinical research.

antimicrobial resistance surveillancecentral laboratory microbiology servicesclinical research laboratory servicesin vitro diagnostic device studiesmolecular characterization and detectionpre-clinical studiesreference laboratory services

Intralytix, Inc. is a biotechnology company based in Columbia, Maryland, that develops bacteriophage-based products for food safety, dietary supplements, and human therapeutics. It pioneered the world's first phage-based FDA clearance for food safety (ListShield) in 2006 and holds FDA and USDA approvals for multiple phage food safety products. The company also runs clinical-stage phage therapy programs targeting antibiotic-resistant infections.

1,500L fermentationAI/ML-driven phage manufacturingbacteriophage discoverycGMP manufacturingcommercial spray drying

JelikaLite is a clinical stage medical technology company developing a transformational neuromodulation platform for unmet needs in developmental pediatric disorders. Its lead product, Cognilum, is a home-based LED-based device for children with autism, designed to improve responsiveness, speech, and social interaction. The company received FDA Breakthrough Device Designation and FDA Non-Significant Risk Device Study Designation.

medical device developmentNeuromodulationtranscranial photobiomodulation

JPTechnologies develops wireless incontinence sensors and Sensor Tags for remote patient monitoring. The sensors detect and identify incontinence events (urinary, fecal, combination) as they occur, providing real-time data on patient conditions so caregivers can direct timely care and reduce rates of incontinence-associated dermatitis and pressure ulcers.

real-time sensor dataremote monitoring

Kansas Medical Clinic (KMC) is a specialty-clinic group in Kansas and Missouri that has provided health care for over 25 years. It specializes in Dermatology, Hair Restoration, MedSpa, Gastroenterology, and a Research Center, and offers Image-Guided Superficial Radiation Therapy for skin cancer.

ColonoscopyDermatologyDiamondGlowEndoscopyGastroenterologyhair restorationHydraFacialImage-Guided Superficial Radiation TherapyLaser Hair RemovalMedSpamicroneedling

Kentucky Pediatric Research, Inc. (doing business as Kentucky Pediatric/Adult Research) has been participating in pharmaceutical sponsored clinical trials since 1986 and has conducted approximately 600 Phase I-IV trials in a wide range of therapeutic areas, specializing in vaccines and anti-infectives. It is a dedicated outpatient research department within a large rural pediatric practice, Physicians to Children & Adolescents, PSC, in Bardstown, KY.

anti-infective researchPhase I-IV trialsvaccine research

Kiniksa Pharmaceuticals is a global biopharmaceutical company founded in 2015 that finds and delivers novel treatments for patients with significant unmet need, with a focus on cardiovascular diseases and immune modulation. Its portfolio includes an FDA-approved therapy and clinical-stage assets, including KPL-387, an investigational monoclonal antibody IL-1 receptor antagonist being evaluated in the Phase 3 PASTORALE trial in recurrent pericarditis.

immune modulationin-licensing and out-licensingresearch and development